About imiglucerase
Recombinant enzyme replacement therapy
Used for
- Long-term enzyme replacement for type 1 Gaucher disease
- Long-term enzyme replacement for type 3 Gaucher disease
Usual adult dose
Usually 60 units/kg by intravenous infusion every two weeks; dose is individualized.
Usual dose in children
Usually 60 units/kg by intravenous infusion every two weeks; dose is individualized.
Common side effects
- Infusion-related reactions, including fever, chills, or flushing
- Headache, dizziness, or fatigue
- Nausea, vomiting, or abdominal discomfort
- Rash, itching, or hives
Important warnings
- Serious allergic reactions, including anaphylaxis, can occur during or after infusion.
- Antibodies to imiglucerase may develop and can increase reaction risk.
- Infusions require monitoring, especially for people with previous allergic reactions.
- Not a treatment for Gaucher disease type 2.
Pregnancy
Use during pregnancy only when clearly needed; evidence is limited, and untreated Gaucher disease also carries risks.
Breastfeeding
It is unknown whether imiglucerase passes into breast milk; consider benefits and risks with a clinician.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.